Medicaid Preferred Drug List (PDL) Program: Round 1 Annual Drug Class Review Pharmacy and Therapeutics Committee Meeting Monday, September 20, 2004 9:00 a.m., DMAS Board Room DRAFT AGENDA

• Welcome and Introductions

Patrick W. Finnerty, Director

• Comments from the Secretary of Health and Human Resources

The Honorable Jane H. Woods, Secretary of Health and Human Resources

• Comments from the Chairperson

Randy Axelrod, M.D., Chairman

• Open Issues

Patrick W. Finnerty, Director Randy Axelrod, M.D., Chairman

- o PDL Multisource and Product Availability Policy
- o Long Acting Narcotics Class Discussion

 Acceptance of Minutes from April 21, 2004 Meeting **P&T Committee Members**

- Drug Class Discussions for Round 1 Annual Review
 - HMG CoA Reductase Inhibitors (Statins)
 - Selective Cox-2 Inhibitors and NSAIDS
 - Proton Pump Inhibitors (PPIs)
 - Angiotensin II Receptor Blocking Agents (ARBs)
 - Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
 - Inhaled Corticosteroids
 - Nasal Steroids
 - Beta Adrenergics
 - Beta Blockers
 - Calcium Channel Blockers
 - H2 Antagonists
 - Second Generation Antihistamines (LSAs)
 - Sedative Hypnotics

P&T Committee Members

Confidential Meeting

Confidential Meeting for P&T Committee Members, DMAS, and FHSC Pursuant to 42 U.S.C. § 1396r-8 to discuss pricing information

• Criteria Discussions for Round 1 Annual Review

P&T Committee Members

• P&T Committee Discussion

Randy Axelrod, M.D.
P&T Committee Members

• Next Meeting – October 6, 2004, 1:00 p.m.

Randy Axelrod, M.D., Chairman